AdAlta
ASX:1ADMelbourne, Australia· Est.
Australian biotech delivering CAR‑T and i‑body therapies for solid tumours, fibrosis and malaria.
Is this your company? Claim your profile to update info and connect with investors.
Claim profileAI Company Overview
Australian biotech delivering CAR‑T and i‑body therapies for solid tumours, fibrosis and malaria.
OncologyFibrosisInfectious Disease
Technology Platform
Proprietary i‑body single‑domain antibody platform and CAR‑T cell therapy platform, leveraging Asian discovery and Australian GMP manufacturing.
Opportunities
Advancing AD‑214 into Phase II and initiating CAR‑T Phase I trials could unlock on‑licensing deals; malaria prophylaxis via WD‑34 offers a large global market.
Risk Factors
Clinical trial failure, reliance on external financing, and regulatory hurdles could delay or limit commercialization.
Competitive Landscape
Competes with established CAR‑T players (e.g., Novartis, Kite) and fibrosis developers; differentiation lies in its i‑body platform and East‑to‑West licensing model.